Latest Articles

Publication Date
All News Scientific
Fertility-Sparing Surgery Holds Its Ground Against a Rare Ovarian Tumor - Bioengineer.org

Fertility-Sparing Surgery Holds Its Ground Against a Rare Ovarian Tumor Bioengineer.org

Published: Oct. 6, 2026, 3:40 p.m.
Read Full Article
Two drugs approved separately eliminate 60% of endometrial tumors when combined in trials in Catalonia - APD Noticies

Two drugs approved separately eliminate 60% of endometrial tumors when combined in trials in Catalonia APD Noticies

Published: Sept. 19, 2026, 10:17 a.m.
Read Full Article
Two drugs approved separately eliminate 60% of endometrial tumors when combined in trials in Catalonia - apdnoticies.com

Two drugs approved separately eliminate 60% of endometrial tumors when combined in trials in Catalonia apdnoticies.com

Published: Sept. 19, 2026, 10:17 a.m.
Read Full Article
Exclusive BAC Article: Faeth Therapeutics; Year-End 2026 PIKTOR Endometrial Cancer Data, Breast Cancer Interim Results 2027, Solid Tumor Expansions, And Catalysts (NASDAQ:FTH) - Seeking Alpha

Exclusive BAC Article: Faeth Therapeutics; Year-End 2026 PIKTOR Endometrial Cancer Data, Breast Cancer Interim Results 2027, Solid Tumor Expansions, And Catalysts (NASDAQ:FTH) Seeking Alpha

Published: Aug. 17, 2026, 7:11 p.m.
Read Full Article
Ovarian Carcinoma Presenting Mucoepidermoid Carcinoma-Like Features in Association With Seromucinous Borderline Tumor: A Real Seromucinous Carcinoma? - Cureus

Ovarian Carcinoma Presenting Mucoepidermoid Carcinoma-Like Features in Association With Seromucinous Borderline Tumor: A Real Seromucinous Carcinoma? Cureus

Published: Aug. 15, 2026, 7:38 a.m.
Read Full Article
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - BioSpace

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy BioSpace

Published: July 15, 2026, 3:11 p.m.
Read Full Article
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - Business Wire

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy Business Wire

Published: July 15, 2026, 10:45 a.m.
Read Full Article
Endometrial cancer: MSS tumors may benefit from ICI when NK and T-cell activity is high - Vera Health

Endometrial cancer: MSS tumors may benefit from ICI when NK and T-cell activity is high Vera Health

Published: June 26, 2026, 7:57 a.m.
Read Full Article
An AI model decodes tumor mutations to predict treatment response - Drug Discovery News

An AI model decodes tumor mutations to predict treatment response Drug Discovery News

Published: June 1, 2026, 7:29 p.m.
Read Full Article
Analysis of Tumor-Associated Macrophages (TAM) Using Cluster of Differentiation 68 (CD68) Immunohistochemical Marker in Endometrial Carcinoma - Cureus

Analysis of Tumor-Associated Macrophages (TAM) Using Cluster of Differentiation 68 (CD68) Immunohistochemical Marker in Endometrial Carcinoma Cureus

Published: May 31, 2026, 4:44 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!